Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinlarebant extension study for Stargardt disease
ACTRN12623001328662Phase 2Active, not recruiting
- Sponsor
- RBP4
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2 trial of tinlarebant, sponsored by RBP4. Started Nov 2023; status: active, not recruiting.
02
Drugs
tinlarebant
Beyond the preview
Go deeper on ACTRN12623001328662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001328662.